Lumipulse® G Total Tau Assay

Chemiluminescent assay kit for quantitative detection of phosphorylated tau-181 (p-tau181) protein in human serum or plasma. Used for early diagnosis and monitoring of neurodegenerative diseases, particularly Alzheimer's disease and other tauopathies. Provides high sensitivity and specificity for tau pathology assessment in clinical and research laboratories.

Enzyme-linked immunoassay kit for quantitative detection of phosphorylated tau-181 (p-tau181) in human serum or plasma. Designed for early diagnosis and monitoring of neurodegenerative diseases, particularly Alzheimer's disease and dementia. Provides rapid, reliable biomarker measurement for clinical and research applications.

Chemiluminescence immunoassay for measuring procalcitonin levels, used for infection and sepsis assessment in clinical diagnostics.

Chemiluminescent immunoassay kit for detecting neurofilament protein biomarkers associated with Alzheimer's disease. Enables early diagnosis and disease monitoring in clinical laboratory settings. Provides quantitative measurement with high sensitivity and specificity for neurodegenerative disease assessment.

Rapid blood-based assay for traumatic brain injury diagnosis using dual biomarkers (GFAP and UCH-L1) with magnetic particle immunoassay technology. Delivers results in 15-50 minutes on a fully automated platform, enabling quick and accurate detection of brain concussions and traumatic brain injuries in clinical settings.

In vitro diagnostic assay kit for quantitative detection of Alzheimer-associated neurofilament protein using fluorometric chromatography. Enables early-stage diagnosis and monitoring of neurodegenerative disease progression in clinical laboratories. Provides rapid, sensitive biomarker measurement for cognitive impairment assessment.

Chemiluminescent assay kit for quantitative detection of beta amyloid 1-42 in patient samples. Designed for early diagnosis and monitoring of Alzheimer's disease and neurodegenerative disorders. Provides rapid, sensitive results using chemiluminescent immunoassay methodology for clinical laboratory use.

Chemiluminescence immunoassay for detection of hypertension-related biomarkers. Part of the company's specialized marker detection portfolio. Supports cardiovascular risk assessment and hypertension management.

A multiplex assay for research use only (RUO) designed to quantitatively detect and measure three neurological biomarkers: phosphorylated tau 181 (pTau 181), phosphorylated tau 231 (pTau 231), and total tau in human samples. The assay has dynamic ranges of 2.5 pg/ml to 320 pg/ml for pTau variants and 0.625 pg/ml to 160 pg/ml for total tau. It can be used with serum (recommended), plasma, or cell culture supernatates for Alzheimer's disease and other neurodegenerative disease research.

A multiplex assay for research use only (RUO) designed to quantitatively detect and measure two neurological biomarkers: glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in human samples. The assay can be used with serum (recommended), plasma, or cell culture supernatates for research applications in stroke, Alzheimer's disease, Parkinson's disease, and other neurological conditions. This product is not intended for traumatic brain injury (TBI) diagnostic use.

Quantitatively determines phosphorylated Tau 217 concentration in EDTA plasma using chemiluminescence analyzer technology. Supports neurodegenerative disease research and diagnostics.

A multiplex assay for research use only (RUO) designed to quantitatively detect and measure ubiquitin C-terminal hydrolase-L1 (UCH-L1) biomarker in human samples. The assay has a dynamic range of 6.25 pg/ml to 800 pg/ml with a limit of detection of 0.788 pg/ml. It can be used with serum (recommended), plasma, or cell culture supernatates for neurological disease research applications.